



Published in final edited form as:

Curr Opin Gastroenterol. 2018 September ; 34(5): 330–335. doi:10.1097/MOG.0000000000000456.

Management of Acute Pancreatitis in the First 72 hours

Theodore W. James, MD¹ and Seth D. Crockett, MD, MPH¹

¹Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina

Abstract

Purpose of Review—Acute pancreatitis (AP) is a common condition that affects patients with varying degrees of severity and may lead to significant morbidity and mortality. This article will review the current paradigm in AP management within the first 72 hours of diagnosis.

Recent Findings—Patients presenting with AP should be evaluated clinically for signs and symptoms of organ failure in order appropriately triage. Initial management should focus on fluid resuscitation, with some data to support Ringer’s lactate over normal saline. Routine use of prophylactic antibiotics in AP is not recommended, nor is urgent endoscopic retrograde cholangiopancreatography (ERCP) in the absence of concomitant acute cholangitis. Early oral feeding should be encouraged, not avoided, and use of parenteral nutrition is discouraged. Cholecystectomy during the same admission of biliary pancreatitis should be performed in order to prevent future AP episodes. Patients with AP secondary to alcohol should receive alcohol counseling. Finally, there is ongoing interest in the development of prognostic laboratory tests in AP and pharmacological therapies to reduce the inflammation that occurs in AP.

Summary—AP is a common and heterogeneous condition with the potential for significant morbidity. Best practices in AP management focus on triage, hydration and enteral feeding.

Keywords

Acute pancreatitis; ERCP; gallstones; cholecystectomy; resuscitation; SIRS

1.0 Introduction

Acute pancreatitis (AP) is a common condition with an annual cost of 2.6 billion dollars.^{1,2} While the overall population mortality rate for AP has remained unchanged, the incidence appears to be increasing.^{3,4} No pharmacological therapy currently exists to treat AP, however data from both observational studies and randomized controlled trials have established best practices that lead to reduced morbidity and mortality in AP. This article

Corresponding author: Seth D. Crockett, MD MPH, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, CB 7080, Chapel Hill, NC 27599, Phone number: +1-919-962-2608, Fax number: +1-984-974-0744, seth_crockett@med.unc.edu.

Conflicts of interest

The authors declare no conflicts of interest.

Conflicts of interest:

Dr. Crockett declares no conflicts of interest.

Dr. James declares no conflicts of interest.

will briefly describe the diagnosis, etiology and prognosis of AP followed by the current paradigms in AP management within the first 72 hours of diagnosis - a period during which appropriate risk stratification and management is critical to optimize patient outcomes for this disease. A number of recent guidelines have addressed this topic, including from the American College of Gastroenterology (ACG),⁵ the International Association of Pancreatology (IAP) and the American Pancreatic Association (APA),⁶ and, most recently, the American Gastroenterological Association (AGA).⁷ Relevant recommendations from these expert groups will be summarized below.

2.0 Main Text

Diagnosis

The diagnosis of AP is established by the presence of at least 2 of the following: stereotypical abdominal pain, serum amylase and/or lipase greater than three times the upper limit of normal, and/or characteristic findings on abdominal imaging.^{8,9} Patients with AP typically present with mid-epigastric and/or right upper quadrant pain that is constant, stabbing in character with radiation to the back or flank. Contrast-enhanced computed tomography (CT) and/or magnetic resonance imaging (MRI) of the pancreas should be reserved for patients in whom the diagnosis is uncertain from clinical and laboratory evaluation alone or patients who fail to improve clinically within the first 72 hours of hospitalization.^{10,11} Figure 1 demonstrates CT imaging of a patient presenting with acute biliary pancreatitis.

Etiology

Gallstones and alcohol are by far the most common causes of AP and thus transabdominal ultrasound and alcohol use history should be obtained in all patients presenting with the condition.^{12,13} Alcohol-induced AP is generally considered to require > 50 g of alcohol per day, though less than 5% of chronic alcoholics develop acute pancreatitis for reasons that are uncertain.^{14,15,16} In the absence of gallstones or a significant history of alcohol use, a serum triglyceride level should be obtained and considered the cause if > 1,000 mg/dl.^{17,18} In medication induced pancreatitis, the most well-established agents are 6-mercaptopurine or azathioprine, isoniazid, loop diuretics and didanosine.¹⁹ Though rare, a pancreatic tumor or cystic neoplasm should be considered as a cause of AP in patients older than age 40 without another obvious etiology.^{20,21} Post-ERCP pancreatitis is the most common serious adverse event attributed to the procedure, though there is debate over how to define this entity.^{22,23} Most studies use the consensus definition which requires the presence of new or worsened abdominal pain, amylase at least three times normal at more than 24 hours after the procedure, and requiring admission or prolongation of planned admission to 2–3 days.^{24,25} Idiopathic AP is defined as pancreatitis with no etiology established after initial laboratory tests, transabdominal ultrasound and CT and should be referred to a center of expertise for further evaluation.^{5,26}

Prognosis

Initial evaluation of a patient with AP should include assessment of systemic inflammatory response criteria and resuscitative measures should be initiated if needed. Numerous AP

severity scoring systems exist to assist in predicting a patient's clinical course, however many are cumbersome to calculate and often take >72 hours to become positive, at which point the patient's clinical course is likely obvious. These scores, including APACHE II, Ranson and Glasgow demonstrate relatively poor positive predictive value.²⁷ Even new scoring systems, including the Bedside Index of Severity in Acute Pancreatitis (BISAP), have not been shown to be more accurate than the previous scoring systems.^{28,29}

In general, the current practice in determining AP severity is based upon the revised Atlanta criteria (Table 1).⁹ Mild AP is defined by absence of organ failure or local complications; moderately severe AP is defined by transient organ failure (less than 48 hours) and/or local complications; severe AP is defined by persistent organ failure (greater than 48 hours). Organ failure is typically defined using the Modified Marshall scoring system for organ dysfunction (Table 2).³⁰ Patients with severe AP should be admitted to an intensive care unit or intermediary care setting whenever possible.⁵ Factors associated with worse outcomes in AP include advanced age, multiple comorbid health problems, elevated body mass index, presence of systemic inflammatory response syndrome, elevated BUN and /or hematocrit, pleural effusions and/or infiltrates and altered mental status.^{31,32,33,34}

Management - Fluid resuscitation

Fluid therapy to prevent hypovolemia and organ hypoperfusion is a well-established cornerstone of sepsis care, which has numerous physiological similarities to AP.³⁵ Typical goal-directed therapy focuses on heart rate, mean arterial pressure, central venous pressure, urine output, blood urea nitrogen concentration, and hematocrit. These goals are outlined in Table 3. Recent AGA, ACG, and IAP/APA guidelines recommend goal directed therapy for fluid resuscitation of AP patients utilizing various parameters.^{5,6,7} However, it should be acknowledged that the evidence supporting these recommendations is relatively weak, and compared to non-targeted therapy, there is not clear evidence that goal-directed therapy results in significant improvement in important outcomes such as mortality, prevention of pancreatic necrosis, or decrease in the rate of persistent multiple organ failure.⁷ Nevertheless, using physiologic metrics to guide initial fluid resuscitation is important both to ensure adequate organ perfusion and to avoid overly aggressive fluid therapy, which can be associated with harms in AP, including respiratory complications and abdominal compartment syndrome.^{36,37} It should be noted that aggressive fluid resuscitation is most useful in the first 12–24 hours of admission, and should generally be curtailed after this point to avoid fluid overload.^{5,38,39}

Two randomized controlled trials evaluating Ringer's lactate vs normal saline as the optimal fluid solution for resuscitation demonstrated a reduction in systemic inflammation.^{40,41} These studies may have limited application, however, as they used surrogate markers of severity and did not focus on important clinical outcomes, such as organ failure, necrosis, or mortality. Despite these limitations, Ringer's lactate is recommended by ACG and IAP/APA guidelines when possible because of the theoretical benefits over normal saline.^{5,6} The recommended infusion rate is 250–500 ml per hour, unless there are cardiovascular, renal, or other related comorbid conditions present.⁵

Hydroxyethyl starch (HES) has also been used as a resuscitative fluid in AP⁴². However, the studies to date failed to demonstrate improved mortality compared to fluid resuscitation without HES and in one trial multiple organ failure was significantly increased in patients receiving HES fluids.^{43, 44} For these reasons, HES-containing fluid is not recommended as a resuscitative agent in AP.

Management – Prophylactic Antibiotics

Mortality doubles when pancreatic or peripancreatic necrosis becomes infected in patients with organ failure.⁴⁵ Previous rationale for administering prophylactic antibiotics was in hopes of reducing the risk for infected necrosis and thereby improving morbidity and mortality. In patients with predicted severe AP and necrotizing pancreatitis older trial data suggest that prophylactic antibiotics were associated with a reduction in the risk of infected pancreatic and peripancreatic necrosis. Recent trial data (since 2002), however, demonstrate no differences in risks of infected pancreatic and peripancreatic necrosis or mortality.⁴⁶ In patients with mild AP there appears to be no role for prophylactic antibiotics in the absence of cholangitis or other extrapancreatic infections. Further, prophylactic antibiotics have not shown an impact on the rates of persistent single organ failure, multiple organ failure, and hospital length of stay.⁴⁷ Accordingly, recent ACG and AGA guidelines have recommended against the routine use of prophylactic antibiotics in AP patients.^{5,7}

Management – Enteral Feeding

Historical management of AP allowed the patient to take little by mouth in order to avoid a theoretical risk of further stimulating an inflamed pancreas. This paradigm has shifted dramatically over the last decade as further evidence has accrued to suggest early feeding does not exacerbate pancreatic parenchymal inflammation, and is actually beneficial in AP. This rationale stems from the understanding that enteral nutrition likely serves to protect the mucosal barrier of the gut and reduce bacterial translocation. This in turn may reduce the risk of developing infected pancreatic and peripancreatic necrosis.⁴⁸

Delayed feeding (generally defined as >24 hours) is associated with higher rates of infected peripancreatic necrosis, multiple organ failure, and total necrotizing pancreatitis.^{49,50,51} Success of early feeding has been demonstrated with low-fat, normal fat, and soft or solid consistency and thus it is not necessary to start AP patients on a clear liquid diet before advancement to a solid diet.^{52,53} Patients who cannot tolerate an oral diet may require enteral tube placement for nutritional support, however the risk of aspiration should be considered in patients with severe AP. There does not appear to be an advantage to post-pyloric tube placement over gastric tube placement.⁵⁴ There is, however, clear evidence demonstrating enteral nutrition over total parenteral nutrition (TPN) is associated with reduced risk of infected peripancreatic necrosis and multiple organ failure.^{55,56} For this reason, TPN use in AP is discouraged.

Management – Urgent ERCP

Urgent ERCP (typically defined as occurring within the first 72 hours) is indicated in patients with acute cholangitis regardless of the presence of acute biliary (i.e. gallstone) pancreatitis.^{57,58} However, in patients with gallstone pancreatitis who do not have

cholangitis, the role of ERCP has been debated. Data from randomized controlled trials on this topic show that compared to conservative management, urgent ERCP in gallstone pancreatitis has not been demonstrated to improve critical outcomes, such as mortality and multiple organ failure, infected pancreatic and peripancreatic necrosis, or total rates of necrotizing pancreatitis.^{59,60,61,62} Thus, urgent ERCP is typically not recommended in AP in the absence of acute cholangitis. There may be a reduction in hospital length of stay for patients with AP undergoing ERCP, though this was only demonstrated in a single study.⁶³

Management – Cholecystectomy

In cases of AP secondary to gallstone disease, cholecystectomy should be performed to prevent recurrent episodes of AP.⁶⁴ The optimal timing of surgery weighs the challenges of operating on a patient with an acutely inflamed pancreas against the risk for recurrent gallstone-related complications. Patients discharged without a cholecystectomy have a significant risk of recurrent AP and/or cholangitis.⁶⁵ Data from a randomized controlled clinical trial found that cholecystectomy during the initial admission for patients with gallstone pancreatitis was associated with reduction in mortality and gallstone-related complications, readmission for recurrent pancreatitis, and pancreaticobiliary complications.⁶⁶ The current recommendations favor cholecystectomy during the same admission when the etiology of AP is determined to be gallstones.⁴³

Management – Alcohol Counseling

In patients with a first attack of AP with a clear history of alcohol use, counseling has demonstrated a reduction in total hospital admission rates and can reduce the risk of AP recurrence.^{67,68} The SBIRT (Screening, Brief Intervention, and Referral to Treatment) approach to alcohol counseling is effective in reducing alcohol consumption.⁶⁹ Therefore, because reduction or cessation of alcohol abuse clearly reduces the risk of recurrent alcoholic AP,⁷⁰ and given the negligible harms and relatively low cost of the intervention, it is generally recommended that patients presenting with AP secondary to alcohol abuse receive at least brief alcohol counselling during the index admission.

3.0 Conclusion

Current evidence supports the benefit of goal-directed fluid resuscitation and early oral feeding in all patients with AP. Patients with biliary pancreatitis should preferentially undergo same-admission cholecystectomy. Alcohol counseling for patients with alcohol-induced pancreatitis should be provided. Current data do not support the routine use of prophylactic antibiotics in AP or routine ERCP in patients with AP without accompanying cholangitis.

Acknowledgements

Financial support and sponsorship

Dr. James receives research and training support in part by a grant from the NIH (T32DK007634). Dr. Crockett's effort was supported in part, by a grant from the NIH (5KL2TR001109).

References

1. Peery AF, Crockett SD, Barritt AS, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. *Gastroenterology* 2015;149:1731–1741 e3. [PubMed: 26327134]
2. Fagenholz PJ, Fernandez-del Castillo C, Harris NS, et al. Direct medical costs of acute pancreatitis hospitalizations in the United States. *Pancreas* 2007;35:302–7. [PubMed: 18090234]
3. Fagenholz PJ, Castillo CF, Harris NS, et al. Increasing United States hospital admissions for acute pancreatitis, 1988–2003. *Ann Epidemiol* 2007;17:491–7. [PubMed: 17448682]
4. Yadav D, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systemic review. *Pancreas* 2006;33:323–30. [PubMed: 17079934]
5. Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology guideline: management of acute pancreatitis. *The American journal of gastroenterology*. 2013 9;108(9):1400. [PubMed: 23896955]
6. Besselink M, van Santvoort H, Freeman M, et al. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatology*. 2013;13(4 Suppl 2):e1–15. [PubMed: 24054878]
7. Crockett SD, Wani S, Gardner TB, et al. American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. *Gastroenterology*. 2018 3 1;154(4):1096–101. [PubMed: 29409760] ** Reference is of outstanding interest as it is the most recent societal guideline on the management of acute pancreatitis.
8. Malka D, Rosa-Hezode I. Positive and etiological diagnosis of acute pancreatitis. *Gastroenterol Clin Biol* 2001;25:1S153–1S68. [PubMed: 11223588]
9. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis—2012: revision of Atlanta classification and definitions by international consensus. *Gut* 2013;62:102–11. [PubMed: 23100216]
10. Balthazar EJ. Acute pancreatitis: assessment of severity with clinical and CT evaluation. *Radiology* 2002;223:603–13. [PubMed: 12034923]
11. Stimac D, Miletic D, Radic M, et al. The role of non enhanced magnetic resonance imaging in the early assessment of acute pancreatitis. *Am J Gastroenterol* 2007;102:997–1004. [PubMed: 17378903]
12. Johnson C, Lévy P. Detection of gallstones in acute pancreatitis: when and how? *Pancreatology* 2010;10:27–32. [PubMed: 20299820]
13. Moreau JA, Zinsmeister AR, Melton LJ, et al. Gallstone pancreatitis and the effect of cholecystectomy. *Mayo Clin Proc* 63;466:1988.
14. Steinberg W, Tenner S. Medical progress: acute pancreatitis. *New Engl J Med* 1994;330:1198–210. [PubMed: 7811319]
15. Lankisch PG, Lowenfels AB, Maisonneuve P. What is the risk of alcoholic pancreatitis in heavy drinkers?. *Pancreas*. 2002 11 1;25(4):411–12. [PubMed: 12409838]
16. Yadav D, Eigenbrodt ML, Briggs MJ, et al. Pancreatitis: prevalence and risk factors among male veterans in a detoxification program. *Pancreas*. 2007 5 1;34(4):390–8. [PubMed: 17446836]
17. Toskes PP. Hyperlipidemic pancreatitis. *Gastroenterol Clin North Am* 1990;19:783–91.
18. Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. *J Clin Gastroenterol* 2003;36:54–62. [PubMed: 12488710]
19. Badalov N, Baradaran R, Iswara K, et al. Drug induced acute pancreatitis: an evidence based approach. *Clin Gastroenterol Hepatol* 2007;101:454–76.
20. Simpson WF, Adams DB, Metcalf JS, et al. Nonfunctioning pancreatic neuroendocrine tumors presenting as pancreatitis: report of four cases. *Pancreas* 1988;3:223–31. [PubMed: 3375232]
21. Robertson JF, Imrie CW. Acute pancreatitis associated with carcinoma of the ampulla of Vater. *Br J Surg* 1987;74:395–7. [PubMed: 3594134]
22. Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of postERCP complications: a systematic survey of prospective studies. *Am J Gastroenterol* 2007;102:1781–8. [PubMed: 17509029]

23. Kochar B, Akshintala VS, Afghani E, et al. Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials. *Gastrointest Endosc* 2015;81:143–9.e9. [PubMed: 25088919]
24. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. *Gastrointest Endosc* 1991;37:383–93. [PubMed: 2070995]
25. Chandrasekhara V, Khashab MA, Muthusamy VR, et al. Adverse events associated with ERCP. *Gastrointestinal endoscopy*. 2017 1 1;85(1):32–47. [PubMed: 27546389] * Reference is of special interest as it describes the risk factors associated with post-ERCP pancreatitis.
26. Al-Haddad M, Wallace MB. Diagnostic approach to patients with acute idiopathic pancreatitis, what should be done? *World J Gastroenterol* 2008;14:1007–10. [PubMed: 18286679]
27. Mounzer R, Langmead CJ, Wu BU, et al. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. *Gastroenterology*. 2012 6 1;142(7):1476–82. [PubMed: 22425589]
28. Papachristou GI, Muddana V, Yadav D, et al. Comparison of BISAP, Ranson's, APACHE-II, and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis. *Am J Gastroenterol* 2010;105:435–41. [PubMed: 19861954]
29. Wu BU, Johannes RS, Sun X, et al. Early changes in blood urea nitrogen predict mortality in acute pancreatitis. *Gastroenterology* 2009;137:129–35. [PubMed: 19344722]
30. Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. *Crit Care Med*. 1995;23(10):1638–52 [PubMed: 7587228]
31. Lankisch PG, Mahlke R, Blum T, et al. Hemoconcentration: an early marker of severe and/or necrotizing pancreatitis? A critical appraisal. *Am J Gastroenterol* 2001;96:2081–5. [PubMed: 11467635]
32. Mofidi R, Duff MD, Wigmore SJ, et al. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. *Br J Surg* 2006;93:738–44. [PubMed: 16671062]
33. Heller SJ, Noordhoek E, Tenner SM, et al. Pleural effusion as a predictor of severity in acute pancreatitis. *Pancreas* 1997;15:222–5. [PubMed: 9336784]
34. Funnell IC, Bornman PC, Weakley SP, et al. Obesity: an important prognostic factor in acute pancreatitis. *Br J Surg* 1993;80:484–6. [PubMed: 8495317]
35. Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock. *N Engl J Med* 2001;345:1368–77. [PubMed: 11794169]
36. de-Madaria E, Soler-Sala G, Sánchez-Payá J, et al. Influence of fluid therapy on the prognosis of acute pancreatitis: a prospective cohort study. *Am J Gastroenterol* 2011;106:1843–50. [PubMed: 21876561]
37. De Waele JJ, Leppäniemi AK. Intra-Abdominal Hypertension in Acute Pancreatitis. *World J Surg* 2009;33:1128–33. [PubMed: 19350318]
38. Gardner TB, Vege SS, Chari ST, et al. Faster rate of initial fluid resuscitation in severe acute pancreatitis diminishes in-hospital mortality. *Pancreatol*. 2009;9(6):770–6. [PubMed: 20110744]
39. Warndorf MG, Kurtzman JT, Bartel MJ, et al.. Early fluid resuscitation reduces morbidity among patients with acute pancreatitis. *Clinical gastroenterology and hepatology*. 2011 8 1;9(8):705–9. [PubMed: 21554987]
40. Wu BU, Hwang JQ, Gardner TH, et al. Lactated Ringer's solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. *Clinical Gastroenterology and Hepatology*. 2011 8 1;9(8):710–7. [PubMed: 21645639]
41. de-Madaria E, Herrera-Marante I, González-Camacho V, et al. Fluid resuscitation with lactated Ringer's solution vs normal saline in acute pancreatitis: A triple-blind, randomized, controlled trial. *United European gastroenterology journal*. 2018 2;6(1):63–72. [PubMed: 29435315] * Reference is of special interest as it is a high-quality trial evaluating optimal resuscitative fluid in acute pancreatitis.
42. Vege S, DiMagno M, Forsmark CE, et al. Initial medical treatment of acute pancreatitis: AGA Institute Technical Review. *Gastroenterology* 2018.** Reference is of outstanding interest as it is a recent technical review of the evidence for the initial management of acute pancreatitis.

43. Du XJ, Hu WM, Xia Q, et al. Hydroxyethyl starch resuscitation reduces the risk of intra-abdominal hypertension in severe acute pancreatitis. *Pancreas* 2011; 40:1220–1225. [PubMed: 21775917]
44. Zhao G, Zhang JG, Wu HS, et al. Effects of different resuscitation fluid on severe acute pancreatitis. *World J Gastroenterol* 2013;19:2044–2052. [PubMed: 23599623]
45. Werge M, Novovic S, Schmidt PN, Gluud LL. Infection increases mortality in necrotizing pancreatitis: a systematic review and meta-analysis. *Pancreatology*. 2016 9 1;16(5):698–707. [PubMed: 27449605] * Reference is of special interest as it provides high-quality data on the mortality risk related to infectious complications of acute pancreatitis.
46. Lim CL, Lee W, Liew YX, et al. Role of antibiotic prophylaxis in necrotizing pancreatitis: a meta-analysis. *Journal of Gastrointestinal Surgery*. 2015 3 1;19(3):480–91. [PubMed: 25608671]
47. Jiang K, Huang W, Yang XN, Xia Q. Present and future of prophylactic antibiotics for severe acute pancreatitis. *World Journal of Gastroenterology: WJG*. 2012 1 21;18(3):279. [PubMed: 22294832]
48. Windsor AC, Kanwar S, Li AG, et al. Compared with parenteral nutrition, enteral feeding attenuates the acute phase response and improves disease severity in acute pancreatitis. *Gut* 1998;42:431–435. [PubMed: 9577354]
49. Zhao XL, Zhu SF, Xue GJ, et al. Early oral refeeding based on hunger in moderate and severe acute pancreatitis: a prospective controlled, randomized clinical trial. *Nutrition*. 2015 1 1;31(1):171–5. [PubMed: 25441594]
50. Bakker OJ, van Brunschot S, van Santvoort HC, et al. Early versus on-demand nasoenteric tube feeding in acute pancreatitis. *New England Journal of Medicine*. 2014 11 20;371(21):1983–93. [PubMed: 25409371]
51. Eckerwall GE, Tingstedt BB, Bergenzaun PE, Andersson RG. Immediate oral feeding in patients with mild acute pancreatitis is safe and may accelerate recovery—a randomized clinical study. *Clinical Nutrition*. 2007 12 1;26(6):758–63. [PubMed: 17719703]
52. Jacobson BC, Vander Vliet MB, Hughes MD, et al. A prospective, randomized trial of clear liquids versus low-fat solid diet as the initial meal in mild acute pancreatitis. *Clinical Gastroenterology and Hepatology*. 2007 8 1;5(8):946–51. [PubMed: 17613280]
53. Moraes JM, Felga GE, Chebli LA, et al. A full solid diet as the initial meal in mild acute pancreatitis is safe and result in a shorter length of hospitalization: results from a prospective, randomized, controlled, double-blind clinical trial. *Journal of clinical gastroenterology*. 2010 8 1;44(7):517–22. [PubMed: 20054282]
54. Doley RP, Yadav TD, Wig JD, et al. Enteral nutrition in severe acute pancreatitis. *JoP*. 2009 Mar 9;10(2):157–62. [PubMed: 19287109]
55. Gupta R, Patel K, Calder PC, et al. A randomised clinical trial to assess the effect of total enteral and total parenteral nutritional support on metabolic, inflammatory and oxidative markers in patients with predicted severe acute pancreatitis (APACHEE II 6). *Pancreatology*. 2003 1 1;3(5):406–13. [PubMed: 14526151]
56. Kalfarentzos F, Kehagias J, Mead N, et al. Enteral nutrition is superior to parenteral nutrition in severe acute pancreatitis: results of a randomized prospective trial. *BJS*. 1997 12 1;84(12):1665–9.
57. Lai EC, Mok FP, Tan ES, et al. Endoscopic biliary drainage for severe acute cholangitis. *New England Journal of Medicine*. 1992 6 11;326(24):1582–6. [PubMed: 1584258]
58. Chijiwa K, Kozaki N, Naito T, et al. Treatment of choice for choledocholithiasis in patients with acute obstructive suppurative cholangitis and liver cirrhosis. *The American journal of surgery*. 1995 10 1;170(4):356–60. [PubMed: 7573728]
59. Fan ST, Lai E, Mok F, et al. Early treatment of acute biliary pancreatitis by endoscopic papillotomy. *New England Journal of Medicine*. 1993 1 28;328(4):228–32. [PubMed: 8418402]
60. Folsch UR, Nitsche R, Ludtke R, et al. the German Study Group on Acute Biliary Pancreatitis. Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. *N Engl J Med*. 1997 1 23;336(4):237–42. [PubMed: 8995085]
61. Oría A, Cimmino D, Ocampo C, et al. Early endoscopic intervention versus early conservative management in patients with acute gallstone pancreatitis and biliopancreatic obstruction: a randomized clinical trial. *Annals of surgery*. 2007 1;245(1):10. [PubMed: 17197959]

62. Acosta JM, Katkhouda N, Debian KA, et al. Early ductal decompression versus conservative management for gallstone pancreatitis with ampullary obstruction: a prospective randomized clinical trial. *Annals of surgery*. 2006 1;243(1):33. [PubMed: 16371734]
63. Neoptolemos JP, London NJ, James D, et al. Controlled trial of urgent endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy versus conservative treatment for acute pancreatitis due to gallstones. *The Lancet*. 1988 10 29;332(8618):979–83.
64. Yadav D, O’Connell M, Papachristou GI. Natural history following the first attack of acute pancreatitis. *Am J Gastroenterol* 2012;107:1096–1103. [PubMed: 22613906]
65. van Baal MC, Besselink MG, Bakker OJ, et al. Timing of cholecystectomy after mild biliary pancreatitis: a systematic review. *Ann Surg* 2012;255:860–866. [PubMed: 22470079]
66. da Costa DW, Bouwense SA, Schepers NJ, et al. Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. *Lancet* 2015;386:1261–1268. [PubMed: 26460661] * Reference is of special interest as it a well-designed clinical trial that demonstrates the benefits of same-admission cholecystectomy in patients with mild gallstone pancreatitis.
67. Kaner EF, Beyer F, Dickinson HO, et al. Effectiveness of brief alcohol interventions in primary care populations. *Cochrane Database Syst Rev* 2007:CD004148. [PubMed: 17443541]
68. Nordback I, Pelli H, Lappalainen–Lehto R, et al. The recurrence of acute alcohol-associated pancreatitis can be reduced: a randomized controlled trial. *Gastroenterology*. 2009 3 1;136(3):848–55. [PubMed: 19162029]
69. Babor TF, McRee BG, Kassebaum PA, et al. Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse. *Subst Abus*. 2007;28(3):7–30. [PubMed: 18077300]
70. Nikkola J, Rätty S, Laukkarinen J, et al. Abstinence after first acute alcohol-associated pancreatitis protects against recurrent pancreatitis and minimizes the risk of pancreatic dysfunction. *Alcohol and alcoholism*. 2013 3 28;48(4):483–6. [PubMed: 23538610]

4.0**Key Points**

- Acute pancreatitis is defined by two of the following: stereotypical abdominal pain, amylase and/or lipase > 3 times the upper limit of normal and imaging findings consistent with the condition.
- Patients presenting with AP should undergo transabdominal ultrasound to evaluate for gallstone disease and a thorough alcohol use history should be obtained.
- Fluid resuscitation in acute pancreatitis should focus on improving heart rate, mean arterial pressure, central venous pressure, urine output, blood urea nitrogen concentration, and hematocrit. Ringer's lactate is generally favored over normal saline as the resuscitative fluid of choice.
- Early oral feeding should be encouraged in AP and if a patient cannot tolerate oral intake, placement of an enteral feeding tube should be considered.
- Cholecystectomy during the same admission of biliary pancreatitis should be pursued and patient with AP secondary to alcohol should receive counselling on alcohol abuse.




Figure 1: Contrast enhanced computed tomography of a patient presenting with acute pancreatitis from gallstone disease. CT demonstrating characteristic imaging findings of interstitial edematous pancreatitis, with a heterogeneously enhancing, edematous pancreas.

Table 1:

The Revised Atlanta Classification of Acute Pancreatitis (2013)

Mild acute pancreatitis

Absence of organ failure

Absence of local complications

Moderately severe acute pancreatitis

1. Local complications **AND/OR**
2. Transient organ failure (<48 hours)

Severe acute pancreatitis

Persistent organ failure >48 hours

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2:

Modified Marshall scoring system for organ dysfunction.

Organ system	Score				
	0	1	2	3	4
Respiratory (PaO ₂ /FiO ₂ ratio)	> 400	301 – 400	201 – 300	101 – 200	101
Renal (serum creatinine)	< 1.4 mg/dL	1.4 – 1.8 mg/dL	1.9 – 3.6 mg/dL	3.6 – 4.9 mg/dL	> 4.9 mg/dL
Cardiovascular (systolic blood pressure, pH)	> 90 mm Hg	< 90 mm Hg, fluid responsive	< 90 mm Hg, not fluid responsive	< 90 mm Hg, pH < 7.3	< 90 mm Hg, pH < 7.2

A score of 2 in any system defines the presence of organ failure.

Transient organ failure: organ failure resolving after 48 hours; Persistent organ failure: organ failure persisting > 48 hours.

Table 3:

Fluid therapy goals to prevent hypovolemia and organ hypoperfusion in acute pancreatitis²³

Central venous pressure
8 – 12 mm Hg
Mean arterial pressure
65 – 90 mm Hg
Central venous oxygen saturation
>=70%

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript